216 related articles for article (PubMed ID: 9699906)
1. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study.
Yoshida H; Ishikawa T; Ayaori M; Shige H; Ito T; Suzukawa M; Nakamura H
Atherosclerosis; 1998 Jul; 139(1):179-87. PubMed ID: 9699906
[TBL] [Abstract][Full Text] [Related]
2. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
[TBL] [Abstract][Full Text] [Related]
3. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
[TBL] [Abstract][Full Text] [Related]
4. Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients.
Chen MF; Wang TD; Yeh HT; Hsu HC; Lee YT
Eur J Clin Invest; 2001 Aug; 31(8):707-13. PubMed ID: 11473572
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.
Vázquez M; Zambón D; Hernández Y; Adzet T; Merlos M; Ros E; Laguna JC
Br J Clin Pharmacol; 1998 Mar; 45(3):265-9. PubMed ID: 9517370
[TBL] [Abstract][Full Text] [Related]
6. Gemfibrozil decreases autoantibodies against oxidized low-density lipoprotein in men with combined hyperlipidaemia.
Hoogerbrugge N; Kerkhofs LG; Jansen H
J Intern Med; 1998 May; 243(5):355-9. PubMed ID: 9651557
[TBL] [Abstract][Full Text] [Related]
7. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.
Orem C; Orem A; Uydu HA; Celik S; Erdöl C; Kural BV
Coron Artery Dis; 2002 Feb; 13(1):65-71. PubMed ID: 11917201
[TBL] [Abstract][Full Text] [Related]
8. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.
Zambón D; Ros E; Rodriguez-Villar C; Laguna JC; Vázquez M; Sanllehy C; Casals E; Sol JM; Hernández G
Metabolism; 1999 Jan; 48(1):47-54. PubMed ID: 9920144
[TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
Superko HR; Berneis KK; Williams PT; Rizzo M; Wood PD
Am J Cardiol; 2005 Nov; 96(9):1266-72. PubMed ID: 16253595
[TBL] [Abstract][Full Text] [Related]
10. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia.
Yang CY; Gu ZW; Xie YH; Valentinova NV; Yang M; Yeshurun D; Quion JA; Gotto AM
Atherosclerosis; 1996 Sep; 126(1):105-16. PubMed ID: 8879439
[TBL] [Abstract][Full Text] [Related]
11. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
O'Neal DN; O'Brien RC; Timmins KL; Grieve GD; Lau KP; Nicholson GC; Kotowicz MA; Best JD
Diabet Med; 1998 Oct; 15(10):870-7. PubMed ID: 9796889
[TBL] [Abstract][Full Text] [Related]
12. Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia.
Smith WG; Wang J; Dang AQ; Reeves C; Bibbs D; Faas FH
Clin Chim Acta; 2002 Aug; 322(1-2):77-84. PubMed ID: 12104084
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
Civeira F; Cenarro A; Ferrando J; Puzo J; Garcia-Otín AL; Mozas P; Pocoví M
Am Heart J; 1999 Jul; 138(1 Pt 1):156-62. PubMed ID: 10385780
[TBL] [Abstract][Full Text] [Related]
14. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
[TBL] [Abstract][Full Text] [Related]
15. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
Nephron; 1997; 75(3):286-94. PubMed ID: 9069450
[TBL] [Abstract][Full Text] [Related]
16. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
[TBL] [Abstract][Full Text] [Related]
17. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia.
Aberg F; Appelkvist EL; Bröijersén A; Eriksson M; Angelin B; Hjemdahl P; Dallner G
Eur J Clin Invest; 1998 Mar; 28(3):235-42. PubMed ID: 9568470
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
Jen SL; Chen JW; Lee WL; Wang SP
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
[TBL] [Abstract][Full Text] [Related]
19. Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
Knipscheer HC; Nurmohamed MT; Van den Ende A; Plaat B; Pruijs HJ; Mulder WJ; Kastelein JJ
J Intern Med; 1994 Oct; 236(4):377-84. PubMed ID: 7931040
[TBL] [Abstract][Full Text] [Related]
20. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
